logo

For the Inventor, By the Inventor

Raleigh, NC, United States of America

James L Kelley

USPTO Granted Patents = 19 


Average Co-Inventor Count = 1.9

ph-index = 7

Forward Citations = 175(Granted Patents)


Location History:

  • Cupertino, CA (US) (1989)
  • Raleigh, NC (US) (1989 - 2010)

Company Filing History:

goldMedal6 out of 521 
 
Burroughs Wellcome Co.
 patents
silverMedal6 out of 281 
 
Glaxo Wellcome Inc.
 patents
bronzeMedal4 out of 5 
 
Krenitsky Pharmaceuticals, Inc.
 patents
4. 1 out of 1 
 
Algebra, Inc.
 patent
5. 2 out of 832,843 
Other
 patents

Years Active: 1989-2010

Loading Chart...
Loading Chart...
19 patents (USPTO):Explore Patents
1. 7763612 - Therapeutic amine-arylsulfonamide conjugate compounds (2010-07-27),
2. 7205297 - Substituted 5-alkynyl pyrimidines having neurotrophic activity (2007-04-17),
3. 6916820 - Neurotrophic substituted pyrimidines (2005-07-12),
4. 6583148 - Neurotrophic substituted pyrimidines (2003-06-24),
5. 6440965 - Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system (2002-08-27),
6. 6124284 - Bicyclic amide derivatives and their use as muscle relaxants (2000-09-26),
7. 5872118 - Bicyclic amide derivatives and their use as muscle relaxants (1999-02-16),
8. 5760224 - Arylmorpholine preparation and use (1998-06-02),
9. 5719186 - Amide derivatives and their therapeutic use (1998-02-17),
10. 5708033 - Amide derivatives and their therapeutic use (1998-01-13),
11. 5648347 - Arylmorpholine, preparation and use (1997-07-15),
12. 5240937 - Pharmaceutically active triazolopyridine compounds (1993-08-31),
13. 5166209 - Pharmacologically active compounds (1992-11-24),
14. 5104870 - Heterocyclic pharmaceutical compounds and use (1992-04-14),
15. 5095018 - 3-benzyl-1,2,4-triazolo[4,3-.alpha.] pyrazines (1992-03-10),

Title: James L. Kelley: Innovator in Neurotherapeutics from Raleigh, NC

Introduction: James L. Kelley is a notable inventor based in Raleigh, North Carolina, known for his significant contributions to the field of neurotherapeutics. With a remarkable portfolio of 19 patents, Kelley's work primarily focuses on developing novel compounds that address various neurological disorders.

Latest Patents: Among his most recent innovations are therapeutic amine-arylsulfonamide conjugate compounds, which represent a significant advancement in pharmaceutical formulations. Additionally, he has developed substituted 5-alkynyl pyrimidines, which have shown promising neurotrophic activity. These compounds are particularly important in the treatment of neurodegenerative disorders such as Alzheimer's disease, age-related cognitive decline, nerve injuries, and seizure disorders like epilepsy. His inventions not only contribute to scientific research but also pave the way for effective therapeutic solutions.

Career Highlights: Kelley's career is marked by his associations with prominent pharmaceutical companies, including Burroughs Wellcome Co. and Glaxo Wellcome Inc. Through his work in these organizations, he has played a pivotal role in researching and innovating neurotherapeutic agents that are crucial for patient care.

Collaborations: Throughout his professional journey, Kelley has collaborated with distinguished colleagues such as David Lee Musso and Thomas A. Krenitsky. These partnerships have enriched his innovative process and fostered the development of groundbreaking therapies in neurology.

Conclusion: James L. Kelley's contributions to the field of neurotherapeutics exemplify the impact of dedicated invention and research on health care. His patents not only reflect his innovative spirit but also underline his commitment to improving the lives of those affected by neurological disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…